[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Henrik Wiggers\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100520280","hyperpolarized-mrsi-in-ischemic-heart-disease-a-metabolic-investigation-of-the-heart-muscle-100520280",false,"NCT06054516","Hyperpolarized MRSI in Ischemic Heart Disease: A Metabolic Investigation of the Heart Muscle","Hyperpolarized MRSI in Ischemic Heart Disease: Metabolic Profiling of the Myocardium","Inclusion Criteria:\n\n* Chronic heart failure\n* \\>18 years of age\n* Left ventricular Ejection Fraction (LVEF) of 10 - 60 %\n* Adequate hematologic and organ function.\n* Women who are not postmenopausal or surgically sterile must have a negative serum or urine pregnancy test performed at time of inclusion in the study.\n* Safe and highly effective contraception must be used throughout the study meaning either hormonal anti-conception or an anti-fertility intrauterine device. If the partner is non fertile or the patient has no sexual activities, this is also accepted.\n* Non-insulin dependent Diabetes mellitus is allowed\n* Danish speaking\n* Able and willing to comply after informed consent\n* Ischemic heart disease and referral to viability testing at the Department of Clinical Physiology and Nuclear Medicine at Aarhus University Hospital.\n\nExclusion Criteria:\n\n* Not able or willing to receive heart failure therapy\n* Patients not willing to participate\n* Uncontrolled serious medical condition, such as uncontrolled heart disease, uncontrolled diabetes, intestinal obstruction, uncontrolled hypertension, or recent cerebral ischemia\n* Estimated Glomerular Filtration Rate (eGFR) \\\u003C30 mL\u002Fmin\n* Insulin dependent Diabetes Mellitus\n* Intolerance to Pyruvate","ALL","18 Years","90 Years",{"count":20,"type":21},15,"ESTIMATED","OBSERVATIONAL","This study aims to investigate the potential of using hyperpolarized \\[1-13C\\]-pyruvate magnetic resonance imaging (MRI) to assess metabolic alterations in patients with ischemic heart disease (IHD). Altered myocardial metabolism is recognized as a crucial factor in heart failure and IHD, and modulating cardiac metabolism offers a new approach to treatment. However, current diagnostic modalities use ionizing radiation and have shown limited prognostic value.\n\nHyperpolarization through dynamic nuclear polarization (DNP) enables highly sensitive in vivo detection of metabolic processes. Hyperpolarized \\[1-13C\\]-pyruvate allows visualization of glycolysis-related metabolism, providing insights into the breakdown of glucose and its derivatives. By using this technique, the study aims to differentiate viable from non-viable myocardium in patients with IHD.\n\nThe objectives include implementing hyperpolarized \\[1-13C\\]-pyruvate cardiac MRI to image metabolic flux in the human heart and investigating the potential of this method to distinguish viable from non-viable myocardium in patients with IHD. The study endpoints involve assessing metabolic flux through the pyruvate dehydrogenase complex (PDC) and analyzing ratios of different metabolites, which can indicate the extent of pyruvate oxidation and lactate production.\n\nA cross-sectional study design involving patients with CHF and ischemic heart disease will be used. Patients will undergo hyperpolarized \\[1-13C\\]-pyruvate MRI, PET imaging, late gadolinium enhancement (LGE) MRI, and cardiac magnetic resonance imaging (CMR). The study will compare \\[1-13C\\]-pyruvate MRI findings with PET results, allowing for a correlation between metabolic data and traditional imaging techniques. This innovative approach could provide valuable insights into the metabolic changes associated with ischemic heart disease",[25],"Ischemic Heart Disease","RECRUITING","2026-03-04",{"date":29,"type":30},"2026-03-06","ACTUAL",{"date":32,"type":30},"2023-10-13",{"date":34,"type":21},"2027-01-31",{"name":36,"class":37},"Henrik Wiggers","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100409569","blood-pressure-reduction-in-patients-with-asymptomatic-aortic-valve-stenosis-100409569","NCT04613193","Blood Pressure Reduction in Patients With Asymptomatic Aortic VALVE Stenosis","BP-AVALVE","Inclusion Criteria:\n\n* Aortic valve peak velocity (Vmax) of 3.0-5.0 m\u002Fs and\u002For aortic valve area (AVA) ≤ 1.2 cm2\n* Blood pressure: SBP \\>= 127 mmHg measured by BP-TRU\n* LVEF ≥ 50%\n* Age \\> 18 years\n* Safe birth control management (intrauterine devices or hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)) for women of childbearing potential.\n* Negative urine-HCG for women of childbearing potential\n* Ability to understand the written patient information and to give informed consent.\n\nExclusion Criteria:\n\n* Symptoms due to AS\n* Symptomatic orthostatic hypotension and\u002For one minute standing SBP \\\u003C 110 mmHg (16).\n* Suspicion of secondary hypertension\n* Participation in other randomized drug study (device studies accepted)\n* Moderat to severe aortic valve regurgitation e.g. vena contracta \\> 5 mm, assessed by echocardiography)\n* Known or suspected ischemic heart disease (coronary angiography with \\>70% stenosis in a major epicardial vessel, symptoms or signs of myocardial ischemia, e.g. angina pectoris, wall motion abnormalities). Patients who have previously undergone complete revascularization of major coronary arteries due to angina pectoris are eligible for inclusion.\n* Significant coronary obstructive lesions detected by baseline Cardiac CT that requires a revascularisation procedure.\n* eGFR \\\u003C 30 ml\u002Fmin or end-stage renal disease\n* Other disease, comorbidity or treatment making the subject unsuitable for study participation as judged by the investigator",{"count":47,"type":21},200,"INTERVENTIONAL",[50],"NA","The aim of this study is to investigate the effect of strict blood pressure control versus conventional care in patients with asymptomatic moderate to severe aortic valve stenosis.\n\nThe study is a randomized (1:1), open label, controlled intervention trial.\n\nHypothesis:\n\n1. Strict BP control for 12 months reduces the progression of LV remodelling compared to conventional treatment.\n2. Strict BP control for 2 years reduces the increase in aortic valve calcification and LV remodelling compared to conventional treatment.\n3. Strict BP reduction for up to 10 years reduces the need for aortic valve replacement and cardiovascular events compared to conventional care.",[53,54,55],"Aortic Valve Stenosis","Hypertension,Essential","Heart Failure",[53,57,58],"Hypertension","Heart failure","2020-10-27",{"date":61,"type":30},"2020-11-03",{"date":63,"type":30},"2019-03-01",{"date":65,"type":21},"2031-06-01",{"name":36,"class":37},6,""]